Consumer Behavior

PREDICTION BY

FOLLOW-UP

GLP-1 drugs have had a significant impact on markets, consumer behavior, and brand strategy, validating this prediction.

PREDICTION BY

FOLLOW-UP

Throughout 2024–2026, 'Shrinkflation' (smaller packs at higher effective prices) has been widely reported in media, generating significant consumer and regulatory anger. The practice Ritson defines as 'maximiniflation' is consistent with this. As of mid-2026, there has been sustained, visible consumer anger, with public discourse increasingly focusing on 'stealth price rises.' The direction and timing of the prediction have been broadly borne out. The exact publication date of the article is not given, but since it is a prediction for 2026, a 2025 publication date is assumed.

PREDICTION BY

FOLLOW-UP

By 2025, leading platforms including Google, Amazon, TikTok, Meta, and major OTAs have integrated AI shopping and recommendation agents. Surveys and usage data from 2025 show rapid growth in AI chat-based travel planning and AI-assisted product discovery. The prediction is consistent with observed 2025 behavior, especially regarding travel recommendations.

PREDICTION BY

FOLLOW-UP

The phenomenon of maximiniflation (reduced product sizes with quiet price increases) is clearly observable, and public, media, and regulatory attention, along with consumer anger, appears to be growing. However, because the prediction is for 'consumer anger in 2026' and the year is still in progress (as of mid-2026), the final outcome cannot yet be definitively scored.

PREDICTION BY

FOLLOW-UP

GLP-1 drugs saw explosive adoption and major impact on consumer behavior and industries, as predicted. While AI also remained prominent, the significant impact of GLP-1 drugs in 2024 supports the \"year of GLP-1\" claim.